Evidence map›Paper›PMID 39342603›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Trends in Stage-Specific Kidney Cancer Incidence in Kazakhstan, 2005-2019.

Nurbek Igissin, Sergey Dyakov, Zhansaya Telmanova, Indira Kudaibergenova, Serik Ayaganov, Dulat Turebayev, Akzhunis Jexenova, Gulnur S Igissinova, Saule Maukayeva, Vladimir Lust and 5 more

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nurbek IgissinResearch Institute of Life and Health Sciences, Higher School of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.ORCID 0000-0002-2517-6315
Sergey DyakovCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID 0000-0001-7566-7094
Zhansaya TelmanovaCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID 0000-0002-2364-6520
Indira KudaibergenovaAsian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan.ORCID 0000-0003-3007-8127
Serik AyaganovHigher School of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.ORCID 0009-0003-6332-5232
Dulat TurebayevCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID 0000-0003-1557-3496
Akzhunis JexenovaAstana Medical University, Astana, Kazakhstan.ORCID 0000-0001-9771-0882
Gulnur S IgissinovaCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID 0000-0001-6881-2257
Saule MaukayevaSemey medical University, Semey, Kazakhstan.ORCID 0000-0002-2679-6399
Vladimir LustAstana Medical University, Astana, Kazakhstan.ORCID 0000-0001-9418-7942
Vladimir GrigorevskyAstana Medical University, Astana, Kazakhstan.ORCID 0009-0009-0132-7973
Alina ShelestyukAstana Medical University, Astana, Kazakhstan.ORCID 0000-0001-7513-0123
Nariman SyzdykovCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID https://orcid.org/00
Ivan ShishkinHigher School of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.ORCID 0009-0007-3620-5541
Zarina BilyalovaCentral Asian Institute for Medical Research, Astana, Kazakhstan.ORCID 0000-0002-0066-235X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim is to analyze the incidence of kidney cancer over a 15-year period, considering factors such as stage, age, sex, and morphological verification in the regional context in Kazakhstan.

methodsThe retrospective study was done using descriptive and analytical methods of oncoepidemiology. The extensive, crude and age-specific incidence rates are determined according to the generally accepted methodology used in sanitary statistics. The data were used to calculate the average percentage change (APС) using the Joinpoint regression analysis to determine the trend over the study period.

resultsAmong the meticulously documented 15,277 cases, a conspicuous male predominance was noted, comprising 53.7% of cases compared to 46.3% in females, with peak incidences observed within the 50-69 age cohorts. The average age at diagnosis exhibited a progressive rise over the study period, with discernible variations observed in age-specific incidence rates, particularly pronounced within the 60-84 age brackets. Noteworthy temporal trends indicated a consistent uptick in crude incidence rates, with distinct regional disparities manifesting higher rates in northern regions relative to their southern and western counterparts. Stratification by cancer stage unveiled a significant surge in stages I-II cases alongside a concomitant decrement in stage III incidences, complemented by reductions in stage IV occurrences and instances of unspecified disease stages. Morphological verification rates displayed regional variations, with an overarching ascending trajectory across most regions, albeit exceptions noted, notably in the Kyzylorda region.

conclusionOur study identified a rise in kidney cancer incidence in Kazakhstan, likely reflecting global trends driven by increased risk factor exposure and incidental imaging findings. Regional disparities and varied stage distributions highlight the complexity of kidney cancer epidemiology. Despite advancements in early detection, delayed diagnosis persists, necessitating improved surveillance and diagnostic practices.

Indexed as

Kidney NeoplasmsNeoplasm StagingAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleFollow-Up StudiesHumansIncidenceKazakhstanMaleMiddle AgedPrognosiscancer rateDynamicsmorphological verificationregionsrenal cancer

Identifiers

PMID39342603
PMCPMC11700335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.